Search
Displaying 571–580 of 1079 results
-
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Research NewsCompany also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
Research NewsIn a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
About Page
The Foundation’s Strategic Council is a group of young professionals with an affinity to the Fighting Blindness mission and represent the next generation of Foundation leaders.
-
Beacon Stories
At seven years old, Hannah had never seen a lightning bug in the summer or a star in the sky. But after her treatment with LUXTURNA, Hannah can now play outside at night with her brothers and has a new bright future in store.
-
Making a stock donation is a powerful way to support the mission of the Foundation Fighting Blindness to drive the research for treatments and cures for blinding diseases affecting 1 in 53 individuals around the world.
-
In the Press
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.
-
Foundation News
This December 17th exclusive conversation and acoustic performance by Kodi Lee of America’s Got Talent will raise awareness and funds to find treatments and cures for blinding diseases.
-
End Blindness 2020 Award Winners include Five Foundation-Funded Investigators
In the PressLive stream ceremony will include Art Garfunkel, Diane Schuur, and Margaret Atwood. A tribute will also be made to Justice Ruth Bader Ginsburg.
-
Foundation News
Mr. Ginsberg brings twenty-five years of rare disease corporate development, finance, strategy, and investment leadership experience.
-
Penn Vet’s William Beltran Elected to the National Academy of Medicine
Research NewsThe veterinary researcher’s canine studies are advancing promising retinal therapies toward clinical trials
